Fischer Imaging appeared to make some progress in its 1997 fourth quarter toward turning the company around, posting an increase in quarterly revenues for the first time in fiscal 1997. But the news wasn't all good: The company reported a net loss for
Fischer Imaging appeared to make some progress in its 1997 fourth quarter toward turning the company around, posting an increase in quarterly revenues for the first time in fiscal 1997. But the news wasn't all good: The company reported a net loss for the year of $13.3 million.
For the fourth quarter (end-December), Fischer posted revenues of $14.8 million, up 1.2% over the $14.6 million reported in the fourth quarter of 1996, when Fischer first felt the impact of a sharp drop in shipments to OEMs. The company reported a net loss of $4.1 million, compared with a net loss of $2.6 million last year.
Despite the slight improvement in quarterly revenues, Fischer's annual figures remained well off last year's performance. For 1997, Fischer had revenues of $56.9 million, a dip of 26.6% compared with 1996 revenues of $77.5 million. The company's net loss swelled from $361,000 in 1996 to $13.3 million in 1997. The 1997 loss included a $2.9 million restructuring charge for consolidation of the firm's manufacturing facilities.
The company's financial performance has been plagued by the loss of OEM business from GE Medical Systems. In recent months, however, the Denver-based firm has moved to shore up its OEM base, landing agreements with Johnson & Johnson and Imagyn Medical Technologies (SCAN 10/29/97). Fischer also has a relationship with Sterling Diagnostic Imaging to manufacture that company's line of DirectRay digital detector systems.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.